BioNTech's Next Act Hinges on Pipeline Delivery as Founders Prepare Their Exit
Published on 09/27/2026 at 03:50 | Editorial boerse-global.de
BioNTech shares finished Friday at €86.55, down 0.9% on the day, yet still up 6.4% since the start of the year. That modest pullback tells only part of the story. Behind the ticker, two forces are pulling in opposite directions: a leadership transition that has yet to be fully worked out, and a clinical pipeline that is quietly making its case.
A Separation Still Under Negotiation
The Mainz-based biotech confirmed last Wednesday that co-founders U?ur ?ahin and Ă–zlem TĂĽreci have established a new company, Arife, also headquartered in Mainz. The venture will focus on researching and developing next-generation mRNA medicines, and both founders intend to leave BioNTech by the end of 2026.
What remains unresolved is the terms of the split. Talks over patents, research assets, financial resources and staffing have run into disagreement, and no contractual agreement has been signed. The Handelsblatt reported on the continuing friction. For BioNTech's management, the priority is securing unrestricted access to key intellectual property and development capacity for its own clinical portfolio — a prerequisite the market views as essential for an orderly handover.
Gotistobart Delivers the Numbers
While those negotiations grind on, the science has been moving faster. Roughly a week ago, BioNTech and partner OncoC4 released updated Phase 3 results from the PRESERVE-003 trial for gotistobart. In patients with pretreated squamous NSCLC, median overall survival reached 18.5 months versus 10.0 months on docetaxel. The confirmatory second stage of the study is ongoing.
Those figures carry weight precisely because Covid-19 revenue is shrinking. Cancer research is increasingly where long-term valuation gets decided, and the pipeline now serves as the fundamental counterweight to the uncertainty surrounding the leadership reshuffle.
Should investors sell immediately? Or is it worth buying BioNTech?
Analysts Split, Institutions Lean In
Sell-side opinion is not uniform. Berenberg reaffirmed its buy rating on September 16 and lifted its price target to $140 from $132. BMO Capital moved the other way about three weeks ago, downgrading the stock to Market Perform from Outperform, citing expected declines in Comirnaty revenue and the absence of robust trial data for pumitamig.
Morgan Stanley, by contrast, sees revaluation potential. The bull case rests on whether BioNTech can post convincing clinical progress in the coming months — progress that would narrow the valuation discount. The breadth of the pipeline offers multiple shots at demonstrating efficacy across cancer indications, and each regulatory milestone would likely reinforce investor confidence.
A Vaccine Approval and a Technical Line in the Sand
On September 17, Health Canada approved the Pfizer and BioNTech vaccine adapted to the Omicron XFG variant — evidence that the partnership remains intact and that the existing portfolio continues to generate revenue. For the market, though, those proceeds matter less for their absolute size than for what they fund: the costly research pipeline.
On the charts, the stock trades above its 200-day moving average of €84.37. Holding that level could draw further institutional interest and fresh capital; slipping below it would risk extending the consolidation.
Governance Housekeeping and the Road Ahead
Shareholders also have an administrative date to watch. The supervisory board has approved the appointment of KPMG AG WirtschaftsprĂĽfungsgesellschaft as independent auditor for the financial year ending December 31, 2027, subject to approval at the next annual general meeting.
None of that will move the needle like clinical news. Setbacks in late-stage development remain a constant threat in biotech — a single failure can wipe out substantial research spending and cast doubt on the timing of future approvals. Add a structural market risk: if interest in the adapted vaccines fades further, financial headroom would tighten noticeably, making pipeline delays even harder to absorb. Investors should brace for abrupt price reactions if unexpected hurdles emerge in ongoing trials.
Ad
BioNTech Stock: New Analysis - 27 September
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
